Press Releases Archives | Page 43 of 116

Cellenkos Announces First Patient Dosed with CK0803 Cell Therapy for Treatment of Amyotrophic Lateral Sclerosis

May 4, 2023 By Cade Hildreth, Founder & President Leave a Comment

First patient dosed with CK0803 Treg cells for treatment of amyotrophic lateral sclerosis (ALS).

CK0803 is derived from clinical-grade umbilical cord blood units

Ongoing Phase 1/1b study evaluating safety and efficacy of CK0803.

HOUSTON, May 2, 2023 — Cellenkos^® Inc., a clinical stage biotechnology company focused on developing allogeneic, off-the-shelf, T regulatory cell therapies for treatment of rare inflammatory diseases and autoimmune disorders, announced that it has dosed the first patient in a Phase 1/1b study evaluating CK0803 for treatment of amyotrophic lateral sclerosis (ALS) (under National Clinical Trial registry NCT05695521). [Read more…]

FUJIFILM Wako Chemicals U.S.A. Commercializes CEPT Cocktail for Research-Use iPSC Applications

May 4, 2023 By Cade Hildreth, Founder & President Leave a Comment

RICHMOND, Virginia — FUJIFILM Wako Chemicals U.S.A., Corporation announces the launch of a ready-to-use small molecule cocktail comprising of Chroman 1, Emricasan, Polyamines, Trans-ISRIB (CEPT Cocktail), a chemical platform for stress-free cell culture and superior survival of induced pluripotent stem cells (iPSCs). CEPT Cocktail is intended for commercial research-use of iPSC applications including disease modeling, organoid generation, drug discovery, toxicology, and pharmacological studies. [Read more…]

Axol Bioscience signs exclusive agreement with The Francis Crick Institute to license iPSC technology

May 3, 2023 By Cade Hildreth, Founder & President 1 Comment

Today, The Francis Crick Institute signed an agreement giving Axol Bioscience exclusive rights to a methodology to generate human pluripotent stem cell (hPSC) derived cells used in drug screening and cardiotoxicity assays.

The technology developed by the Crick is used to generate near-homogeneous populations of hPSC derived left ventricular cardiomyocytes (LVCMs) with improved structural, functional and metabolic maturity. The initial discovery was protected, funded and further developed towards commercial application in-house at the Crick. This work has just been published in Cell Reports Methods and the intellectual property has been licensed to Axol Bioscience for both the production and supply of LVCMs, as well as the provision of screening services. [Read more…]

A new super factory with 29 GMP grade production lines for gene and cell therapy was launched in Shanghai by OBiO technology

April 30, 2023 By Cade Hildreth, Founder & President Leave a Comment

SHANGHAI — On April 21, 2023, OBiO Technology (Shanghai) Corp., Ltd. (“OBiO” or “the Company”), a leading gene and cell therapy CDMO in China, announced the launching of a new GMP manufacturing base, named OBiO Intelli-M. The new base was located in the China (Shanghai) Pilot Free Trade Zone, Lin-Gang Special Area, with 29 production lines and 828,000+ square feet in area, which was one of the biggest super factories for gene therapy in the world. [Read more…]

Stem Genomics opens a local branch partnering with KaryoLogic to bring digital PCR and karyotyping services to North American clients

April 20, 2023 By Cade Hildreth, Founder & President Leave a Comment

April 20, 2023 – Stem Genomics, a French biotech company specializing in innovative testing solutions for the quality control of stem cells for research and therapy, announces the opening of a US branch in the North Carolina Research Triangle region in a new partnership with global karyotyping expert, KaryoLogic Inc. The aim is to bring improved services for assessing the genomic integrity of human pluripotent stem cells (hPSC) to North American-based research scientists. [Read more…]